UNSPSC 51263115: Bupranolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 858YGI5PIT, chemically known as 2-propanol, 1-(tert-butylamino)-3-((6-chloro-m-tolyl)oxy)- (8ci) but generally known as bupranolol, which bears US NIH Compound Identifier 2475. Bupranolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bupranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05984MIG.

UNSPSC 51263115 Bupranolol is a Commodity code that in recent state and local activity captures procurement of pharmaceutical products and related health-system supplies, though the recent opportunities show minimal direct alignment with bupranolol specifically. The code sees solicitation activity from county health departments and state health agencies purchasing pharmacy-related goods and services to support community health and pharmacy benefit programs. Issuing bodies include county governments and state health and human services departments; Seminole County, Florida and the Texas Health and Human Services Commission appear in the recent record.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county's Community Health Building in Sanford, under a two-year contract with one-year renewal option and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs and pharmacy benefit delivery models for self-insured employee health plans and state agencies. The Seminole County procurement requires E-Verify compliance, drug-free workplace certification, and specified insurance coverage; the Texas RFI targets vendors with demonstrated experience in direct contracting with government health plans and flexibility in pricing models. Activity is concentrated in Florida and Texas, with limited breadth evident in the recent-opportunities record.